DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for Abdominal Aortic Aneurysm — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAbdominal Aortic Aneurysm maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for abdominal aortic aneurysm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lipoprotein(a) (LPA) — LPA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TCE · 1.07 Å · ligand (2S)-3-phenyl-2-[(3R)-pyrrolidin-3-yl]propanoic acid (HWF). Experimental structure, not a prediction.
What the evidence adds up to
Abdominal aortic aneurysms are found in 5 to 10% of men over 65. For aneurysms larger than 5.5 cm, elective surgical repair is standard, but even these operations carry significant mortality risk. The UK small aneurysm trial found that for aneurysms between 4 and 5.5 cm there is no difference in outcome between operation and no intervention. Patients with smaller aneurysms currently receive best medical therapy, but no pharmacological treatment has been proven to prevent aneurysm expansion or rupture.
Research published in 2023 has focused on biochemical, genetic, and inflammatory markers associated with aneurysm growth, progression, and rupture. A systematic review of these recent findings describes the role of such markers in AAA pathogenesis and their potential clinical implications for predicting progression and rupture. The review does not report any specific biomarker that has been validated for clinical use or linked to a successful drug intervention.
Endovascular aneurysm repair (EVAR) is a minimally invasive alternative to open surgery that is preferred in many cases, though it is not indicated for all patients. Various advancements in endovascular treatment strategies have been described, but these are procedural refinements, not pharmacological therapies. No drug has been shown in these abstracts to slow AAA growth, prevent rupture, or reduce the need for surgery.
What remains missing is a completed, adequately powered randomised trial testing any drug specifically for AAA growth suppression. Patient stratification by biomarker profile has been proposed but not validated in a prospective treatment study. Funding for such a trial, and for the biomarker validation work that would make it feasible, has not been secured.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
University of Adelaide Press eBooks · 2011 · 0 citations
Pharmacological treatment of aneurysms
AbstractAbdominal aortic aneurysms (AAAs) are present in 5 to 10% of men over the age of 65, and elective surgical intervention has long been the mainstay of treatment. There is widespread consensus that operative repair is the treatment of choice in larger AAAs, where the risk of rupture increases with the size of the aneurysm. However, even elective operations carry a significant mortality risk, and the UK small aneurysm trial has shown that for smaller aneurysms (between 4 and 5.5cm) there is no difference in outcome between operation and no intervention. Currently such patients are treated with best medical therapy, but there has been considerable research into finding a pharmacological treatment to prevent aneurysm expansion and rupture.
BIOCHEMICAL, GENETIC, AND INFLAMMATORY MARKERS ASSOCIATED WITH ANEURYSM GROWTH, PROGRESSION, AND RUPTURE IN ABDOMINAL AORTIC ANEURYSMS
AbstractAbdominal Aortic Aneurysm (AAA) is a life-threatening vascular condition characterized by the progressive dilation of the abdominal aorta, which may lead to rupture. Recent research highlights the role of biochemical, genetic, and inflammatory markers in AAA growth and progression. This paper systematically reviews recent findings (2023) on key biomarkers involved in AAA pathogenesis, focusing on their clinical implications in predicting aneurysm progression and rupture. Understanding these markers is crucial for developing targeted therapies and improving patient outcomes.
Advancements in Endovascular Aneurysm Repair for Various Types of Abdominal Aortic Aneurysms
AbstractAsymptomatic abdominal aortic aneurysm (AAA) is a common and potentially life-threatening condition. It should be repaired before its rupture, because ruptured AAA is nearly uniformly fatal. Elective repair is the most effective management for rupture prevention. Two methods of aneurysm repair are currently available, open surgery and endovascular aneurysm repair (EVAR). Open surgery is capable of treating various complexities of aneurysms, but EVAR is preferred in many cases due to its minimal invasiveness. Although it is not indicated for all patients, various advancements in endovascular treatment strategies allow for active treatment with EVAR in our department. This review article describes these advancements in EVAR.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
